Excipients in medicinal products used in gastroenterology as a possible cause of side effects

Regulatory Toxicology and Pharmacology

Volumn 60, Issue 1, 2011, Pages 93-105

  Ursino, Maria Grazia ^a   Poluzzi, Elisabetta ^a   Caramella, Carla ^b   De Ponti, Fabrizio ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

Adverse reactions; Excipients; Gastrointestinal drugs; Summary of Product Characteristics

Indexed keywords

4 HYDROXYBENZOIC ACID ESTER; ALCOHOL; ASPARTAME; EXCIPIENT; LACTOSE; MANNITOL; MENTHOL; PROPYLENE GLYCOL; SACCHARIN; SILICON DIOXIDE; SORBITOL; SUCROSE;

ARTICLE; CLINICAL PRACTICE; DRUG INDICATION; DRUG INFORMATION; DRUG SAFETY; EXCIPIENT COMPATIBILITY; GEOGRAPHIC DISTRIBUTION; HUMAN; ITALY; NEUROTOXICITY; NONHUMAN; PRESCRIPTION; PRIORITY JOURNAL; RISK FACTOR; UNITED KINGDOM; UNITED STATES;

ADMINISTRATION, ORAL; EXCIPIENTS; GASTROINTESTINAL AGENTS; GASTROINTESTINAL DISEASES; HUMANS; PHARMACEUTICAL PREPARATIONS; SUBSTANCE-RELATED DISORDERS;

EID: 79956015805     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2011.02.010     Document Type: Article

References (74)

1. Adkin D.A., Davis S.S., Sparrow R.A., Huckle P.D., Phillips A.J., Wilding I.R. The effect of different concentrations of mannitol in solution on small intestinal transit: implications for drug absorption. Pharm Res. 1995, 12(3):393-396.
2. Aldrete J.A. Allergy to local anesthetics. JAMA 1969, 209(1):113.
3. Ali M., Rellos P., Cox T.M. Hereditary fructose intolerance. J. Med. Genet. 1998, 35:353-365.
4. Anonymous Saccharin. Review of safety issues. Council on scientific affairs. JAMA 1985, 254(18):2622-2624.
5. Anonymous "Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. Pediatrics 1997, 99(2):268-278.
6. Arola H. Diagnosis of hypolactasia and lactose malabsorption. Scand. J. Gastroenterol. 1994, (Suppl. 202):26-35.
7. Arola H., Tamm A. Metabolism of lactose in the human body. Scand. J. Gastroenterol. 1994, (Suppl. 202):21-25.
8. Arulanantham K., Genel M. Central nervous system toxicity associated with ingestion of propylene glycol. J. Pediatr. 1978, 93(3):515-516.
9. Baldrick P. Pharmaceutical excipient development: the need for preclinical guidance. Regul. Toxicol. Pharmacol. 2000, 32(2):210-218.
10. Belpoggi F., Soffritti M., Padovani M., Degli E.D., Lauriola M., Minardi F. Results of long-term carcinogenicity bioassay on Sprague-Dawley rats exposed to aspartame administered in feed. Ann. NY Acad. Sci. 2006, 1076:559-577.
11. Blumenthal H.J., Vance D.A. Chewing gum headaches. Headache 1997, 37(10):665-666.
12. Brown AM., Masson E. "Hidden" sorbitol in proprietary medicines - a cause for concern?. Pharm. J. 1990, 245:211.
13. Butchko H.H., Stargel W.W., Comer C.P., Mayhew D.A., Benninger C., Blackburn G.L., de Sonneville L.M., Geha R.S., Hertelendy Z., Koestner A., Leon A.S., Liepa G.U., McMartin K.E., Mendenhall C.L., Munro I.C., Novotny E.J., Renwick A.G., Schiffman S.S., Schomer D.L., Shaywitz B.A., Spiers P.A., Tephly T.R., Thomas J.A., Trefz F.K. Aspartame: review of safety. Regul. Toxicol. Pharmacol. 2002, 35(2 Pt 2):S1-93.
14. Camfield P.R., Camfield C.S., Dooley J.M., Gordon K., Jollymore S., Weaver D.F. Aspartame exacerbates EEG spike-wave discharge in children with generalized absence epilepsy: a double-blind controlled study. Neurology 1992, 42(5):1000-1003.
15. Campbell A.K., Waud J.P., Matthews S.B. The molecular basis of lactose intolerance. Sci. Prog. 2005, 88(Pt 3):157-202.
16. Coman D.J., Murray D.W., Byrne J.C., Rudd P.M., Bagaglia P.M., Doran P.D., Treacy E.P. Galactosemia, a single gene disorder with epigenetic consequences. Pediatr. Res. 2010, 67:286-292.
17. Curran B.J., Havill J.H. Hepatic and renal failure associated with amiodarone infusion in a patient with hereditary fructose intolerance. Crit. Care Resusc. 2002, 4:112-115.
18. Dailey J.W., Lasley S.M., Burger R.L., Bettendorf A.F., Mishra P.K., Jobe P.C. Amino acids, monoamines and audiogenic seizures in genetically epilepsy-prone rats: effects of aspartame. Epilepsy Res. 1991, 8(2):122-133.
19. Demey H.E., Daelemans R.A., Verpooten G.A., De Broe M.E., Van Campenhout C.M., Lakiere F.V., Schepens P.J., Bossaert L.L. Propylene glycol-induced side effects during intravenous nitroglycerin therapy. Intensive Care Med. 1988, 14(3):221-226.
20. Dos Santos M.A., Santos Galvao C.E., Morato C.F. Menthol-induced asthma: a case report. J. Investig. Allergol. Clin. Immunol. 2001, 11(1):56-58.
21. Drake M.E. Panic attacks and excessive aspartame ingestion. Lancet 1986, 2(8507):631.
22. Duenas-Laita A., Pineda F., Armentia A. Hypersensitivity to generic drugs with soybean oil. N. Engl. J. Med. 2009, 361(13):1317-1318.
23. Duro D., Rising R., Cedillo M., Lifshitz F. Association between infantile colic and carbohydrate malabsorption from fruit juices in infancy. Pediatrics 2002, 109(5):797-805.
24. Eadala P., Waud J.P., Matthews S.B., Green J.T., Campbell A.K. Quantifying the 'hidden' lactose in drugs used for the treatment of gastrointestinal conditions. Aliment. Pharmacol. Ther. 2009, 29(6):677-687.
25. EMA, 2003. Excipients in the label and package leaflet of medicinal products for human use (EUDRALEX 3BC7A).
26. EMA, 2005. EMA/CHMP/PEG/194810/2005. Reflection paper: formulations of choice for the paediatric population.
27. EMA, 2009. A guideline on summary of product characteristics, September 2009, October 2005.
28. FDA, 2005. Guidance for Industry Nonclinical studies for Safety evaluation of Pharmaceutical Excipients, May 2005.
29. FDA, 2010. Inactive ingredients database. Available online: <> (accessed on 31.12.10). http://www.fda.gov/Drugs/InformationOnDrugs/ucm113978.htm.
30. Findlay S.R., Kagey-Sobotka A., Lichtenstein L.M. In vitro basophil histamine release induced by mannitol in a patient with a mannitol-induced anaphylactoid reaction. J. Allergy Clin. Immunol. 1984, 73(5 Pt 1):578-583.
31. Golden R., Gandy J., Vollmer G. A review of the endocrine activity of parabens and implications for potential risks to human health. Crit. Rev. Toxicol. 2005, 35(5):435-458.
32. Golightly L.K., Smolinske S.S., Bennett M.L., Sutherland E.W., Rumack B.H. Pharmaceutical excipients. Adverse effects associated with inactive ingredients in drug products (Part I). Med. Toxicol. Adverse Drug Exp. 1988, 3(2):128-165.
33. Gulya A.J., Sessions R.B., Troost T.R. Aspartame and dizziness: preliminary results of a prospective, nonblinded, prevalence and attempted cross-over study. Am. J. Otol. 1992, 13(5):438-442.
34. Hannuksela M., Forstrom L. Reactions to peroral propylene glycol. Contact Dermatitis 1978, 4(1):41-45.
35. He T., Priebe M.G., Harmsen H.J., Stellaard F., Sun X., Welling G.W., Vonk R.J. Colonic fermentation may play a role in lactose intolerance in humans. J. Nutr. 2006, 136(1):58-63.
36. Hegde V.L., Venkatesh Y.P. Anaphylaxis to excipient mannitol: evidence for an immunoglobulin E-mediated mechanism. Clin. Exp. Allergy 2004, 34(10):1602-1609.
37. Heyman M.B. Lactose intolerance in infants, children, and adolescents. Pediatrics 2006, 118:1279-1286.
38. Jain N.K., Rosenberg D.B., Ulahannan M.J., Glasser M.J., Pitchumoni C.S. Sorbitol intolerance in adults. Am. J. Gastroenterol. 1985, 80(9):678-681.
39. Janssen P.J., van der Heijden C.A. Aspartame: review of recent experimental and observational data. Toxicology 1988, 50(1):1-26.
40. Johnston K.R., Govel L.A., Andritz M.H. Gastrointestinal effects of sorbitol as an additive in liquid medications. Am. J. Med. 1994, 97(2):185-191.
41. Kawane H. Menthol and aspirin-induced asthma. Respir. Med. 1996, 90(4):247.
42. Kruesi M.J., Rapoport J.L., Cummings E.M., Berg C.J., Ismond D.R., Flament M., Yarrow M., Zahn-Waxler C. Effects of sugar and aspartame on aggression and activity in children. Am. J. Psychiatry 1987, 144(11):1487-1490.
43. Lomer M.C., Parkes G.C., Sanderson J.D. Review article: lactose intolerance in clinical practice - myths and realities. Aliment. Pharmacol. Ther. 2008, 27:93-103.
44. Lowther A., McCormick T., Nedorost S. Systemic contact dermatitis from propylene glycol. Dermatitis 2008, 19(2):105-108.
45. Lutomski D.M., Gora M.L., Wright S.M., Martin J.E. Sorbitol content of selected oral liquids. Ann. Pharmacother. 1993, 27(3):269-274.
46. Marlowe K.F. Urticaria and asthma exacerbation after ingestion of menthol-containing lozenges. Am. J. Health Syst. Pharm. 2003, 60(16):1657-1659.
47. Martin G., Finberg L. Propylene glycol: a potentially toxic vehicle in liquid dosage form. J Pediatr. 1970, 77(5):877-878.
48. McNeill I.Y. Hypersensitivity reaction to mannitol. Drug Intell. Clin. Pharm. 1985, 19(7-8):552-553.
49. Michaelsson G., Pettersson L., Juhlin L. Purpura caused by food and drug additives. Arch. Dermatol. 1974, 109(1):49-52.
50. Micromedex Healthcase Series, 2009. Available online: <> (accessed on 31.12.09). http://www.thomsonhc.com.
51. Montalto M., Gallo A., Santoro L., D'Onofrio F., Curigliano V., Covino M., Cammarota G., Grieco A., Gasbarrini A., Gasbarrini G. Low-dose lactose in drugs neither increases breath hydrogen excretion nor causes gastrointestinal symptoms. Aliment. Pharmacol. Ther. 2008, 28(8):1003-1012.
52. Morgan R.W., Wong O. A review of epidemiological studies on artificial sweeteners and bladder cancer. Food Chem. Toxicol. 1985, 23(4-5):529-533.
53. Nagel J.E., Fuscaldo J.T., Fireman P. Paraben allergy. JAMA 1977, 237(15):1594-1595.
54. Nahata M.C. Safety of "inert" additives or excipients in paediatric medicines. Arch. Dis. Child. Fetal Neonatal Ed. 2009, 94(6):F392-F393.
55. Osterberg R.E., See N.A. Toxicity of excipients - a Food and Drug Administration perspective. Int. J. Toxicol. 2003, 22(5):377-380.
56. Pawar S., Kumar A. Issues in the formulation of drugs for oral use in children: role of excipients. Paediatr. Drugs 2002, 4(6):371-379.
57. Pifferi G., Restani P. The safety of pharmaceutical excipients. Farmaco 2003, 58(8):541-550.
58. Rafnsson V., Ingimarsson O., Hjalmarsson I., Gunnarsdottir H. Association between exposure to crystalline silica and risk of sarcoidosis. Occup. Environ. Med. 1998, 55(10):657-660.
59. Rowe, R.C., Quinn, M.E., Sheskey, P.J., 2009. Handbook of Pharmaceutical Excipients, sixth ed., Pharmaceutical Press.
60. Sanchez-Perez J., Diez M.B., Perez A.A., Jimenez Y.D., Diez G. Allergic and systemic contact dermatitis to methylparaben. Contact Dermatitis 2006, 54(2):117-118.
61. Shaywitz B.A., Sullivan C.M., Anderson G.M., Gillespie S.M., Sullivan B., Shaywitz S.E. Aspartame, behavior, and cognitive function in children with attention deficit disorder. Pediatrics 1994, 93(1):70-75.
62. Shehab N., Lewis C.L., Streetman D.D., Donn S.M. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. Pediatr. Crit. Care Med. 2009, 10(2):256-259.
63. Soffritti M., Belpoggi F., Tibaldi E., Esposti D.D., Lauriola M. Life-span exposure to low doses of aspartame beginning during prenatal life increases cancer effects in rats. Environ. Health Perspect. 2007, 115(9):1293-1297.
64. Sola R., Boj M., Hernandez-Flix S., Camprubi M. Silica in oral drugs as a possible sarcoidosis-inducing antigen. Lancet 2009, 373(9679):1943-1944.
65. Soni M.G., Carabin I.G., Burdock G.A. Safety assessment of esters of p-hydroxybenzoic acid (parabens). Food Chem.Toxicol. 2005, 43(7):985-1015.
66. Suarez F.L., Savaiano D.A., Levitt M.D. Review article: the treatment of lactose intolerance. Aliment. Pharmacol. Ther. 1995, 9(6):589-597.
67. Thorup I., Wurtzen G., Carstensen J., Olsen P. Short term toxicity study in rats dosed with pulegone and menthol. Toxicol. Lett. 1983, 19(3):207-210.
68. Thune P., Granholt A. Provocation tests with antiphlogistica and food additives in recurrent urticaria. Dermatologica 1975, 151(6):360-367.
69. Toxnet, 2009. Drug and Lactation Database (Lactmed). Available online: <> (accessed on 31.12.09). http://toxnet.nlm.nih.gov.
70. Veerman M.W. Excipients in valproic acid syrup may cause diarrhea: a case report. DICP. 1990, 24(9):832-833.
71. Walton R.G. Seizure and mania after high intake of aspartame. Psychosomatics 1986, 27(3):218, 220.
72. Wang Y.M., van Eys J. Nutritional significance of fructose and sugar alcohols. Annu. Rev. Nutr. 1981, 1:437-475.
73. Warshaw E.M., Botto N.C., Maibach H.I., Fowler J.F., Rietschel R.L., Zug K.A., Belsito D.V., Taylor J.S., DeLeo V.A., Pratt M.D., Sasseville D., Storrs F.J., Marks J.G., Mathias C.G. Positive patch-test reactions to propylene glycol: a retrospective cross-sectional analysis from the North American Contact Dermatitis Group, 1996 to 2006. Dermatitis 2009, 20(1):14-20.
74. Wurtman R.J. Aspartame: possible effect on seizure susceptibility. Lancet 1985, 2(8463):1060.